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ABSTRACT 
Background: The number of patients > 65 years of age with malignant gliomas is increasing. Prognosis of these 
patients is worse compared to younger patients. To determine biological differences between malignant gliomas 
of different age groups and help to explain the survival heterogeneity seen in the NOA-08 trial, the prevalence 
and impact of recently established biomarkers for outcome in younger patients were characterized in elderly 
patients. 
Methods: Prevalence of isocitrate dehydrogenase 1 (IDH1) and histone H3.3 (H3F3A) mutations, the glioma 
CpG island methylator phenotype (G-CIMP) and methylation of the alkylpurine DNA N-glycosylase (APNG) and 
peroxiredoxin 1 (PRDX1) promoters was determined in a representative biomarker subset (n=126 patients with 
anaplastic astrocytoma or glioblastoma) from the NOA-08 trial.  
Results: IDH1 mutations (R132H) were detected in only 3/126 patients, precluding determination of an 
association between IDH mutation and outcome. These 3 patients also displayed the G-CIMP phenotype. None 
of the IDH1 wildtype tumors were G-CIMP positive. Mutations in H3F3A were absent in all 103 patients 
sequenced for H3F3A. MassARRAY analysis of the APNG promoter revealed generally low methylation levels 
and failed to confirm any predictive properties for benefit from alkylating chemotherapy. Neither did PRDX1 
promoter methylation show differential methylation or association with outcome in this cohort. In a 170 patient 
cohort from the TCGA database matched for relevant prognostic factors, age ≥ 65 years was strongly associated 
with shorter survival. 
Conclusions: Despite an age-independent stable frequency of O6-methyl-guanyl-methyl-transferase (MGMT) 
promoter hypermethylation, tumors in this age group largely lack prognostically favorable markers established in 
younger glioblastoma patients, which likely contributes to the overall worse prognosis of elderly patients. 
However, the survival differences hint at fundamental further differences between malignant gliomas of different 
age groups. 
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INTRODUCTION 
Glioblastoma (WHO grade IV) is the most common intrinsic brain tumor. The prognosis for patients suffering 
from this disease remains dismal. Age in particular is a strong negative predictor for survival, resulting in a 
population-based median survival of elderly patients (i.e., older than 65 years) of less than 6 months 1. As 
glioblastoma incidence is strongly increasing with age, soon more than half of all glioblastoma patients will be 
considered elderly 2. Improving the therapy of these patients is therefore one of the major challenges in 
neurooncology 3. 
The standard of care in elderly patients is currently ill-defined. This is in part due to the exclusion of elderly 
patients in many clinical trials. The EORTC-NCIC trial, which defined concomitant and adjuvant 
radiochemotherapy with temozolomide as the standard of care, excluded patients older than 70 years 4. In elderly 
patients receiving combined radiochemotherapy, treatment-associated toxicity seems to be higher compared to 
younger patients 5. This especially holds true for radiation-related neurotoxicity, which demonstrates a clear age-
dependency 6,7. To date, involved-field radiotherapy alone is recommended as the standard first-line therapy after 
biopsy or resection in elderly patients 8. However, due to the risk of radiation-induced neurotoxicity, 
temozolomide alone has been explored as a treatment option. Several studies have reported a median overall 
survival comparable to radiotherapy alone with only modest toxicity of temozolomide in this population 9,10. To 
directly compare radiotherapy alone versus temozolomide alone, the German Neuro-Oncology Working Group 
(NOA) conducted a randomized phase 3 trial (NOA-08) in elderly patients. This trial demonstrated a non-
inferiority of temozolomide (1 week on / 1 week off regimen) to focal radiotherapy. Importantly, 
hypermethylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter was established as a very 
strong predictive biomarker for temozolomide sensitivity in elderly patients with malignant glioma. Of note, 
even though median overall survival was short (8.6 months in the temozolomide group vs. 9.6 months in the 
radiotherapy group), in both treatment arms a subset of patients survived considerably longer than two years 11. 
Recently, several other molecular markers have been reported as being either prognostic or even predictive of 
benefit from specific therapeutic interventions in malignant glioma patients. In 2008, Parsons et al. discovered 
mutations in the isocitrate dehydrogenase 1 gene (IDH1) in a subset of glioblastoma patients 12. Subsequently, 
mutations in either IDH1 or IDH2 have been identified in > 70% of WHO grade II and III gliomas and 
secondary glioblastomas 13. In primary glioblastomas, IDH mutations are rare. Importantly, IDH mutations are 
associated with a significantly longer survival time compared to IDH wildtype tumors. Among grade III and IV 
gliomas pooled, IDH has a stronger prognostic impact than the WHO grade. In the same study, the authors also 
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found that in patients with anaplastic astrocytoma and glioblastoma aged 60 years or older, IDH1 mutation is 
found in only 7.5% of the patients (11/146) 14. Analysis of the glioblastoma epigenome revealed a distinct 
hypermethylator phenotype, the glioma CpG island methylator phenotype (G-CIMP), which confers a good 
prognosis 15. G-CIMP positive tumors usually harbor IDH mutations, hence they are common among grade II 
and III gliomas and rare in primary glioblastomas. Genome- and epigenome-wide analysis of glioblastoma 
samples further revealed frequent mutations in the histone 3.3 gene (H3F3A) at K27 or G34 16. Just like IDH 
mutations, both K27M and G34R/V mutations are associated with a distinct epigenetic signature and possibly 
cell of origin each 17. In this study, tumors carrying G34 mutations show a favorable clinical course. Importantly, 
H3F3A and IDH mutations are mutually exclusive, suggesting that mutations in either of these genes represent 
different gliomagenic pathways. While the aforementioned alterations are prognostic, Agnihotri et al. recently 
reported on epigenetic inactivation of alkylpurine DNA N-glycosylase (APNG) as a predictive biomarker for 
benefit from temozolomide treatment 18. APNG is a DNA base excision repair enzyme, which catalyzes removal 
of N3-methyladenine (N3-meA) and N7-methylguanine (N7-meG) from DNA, both of which can be caused by 
temozolomide. APNG expression is regulated through promoter methylation, and in patients with an 
unmethylated MGMT promoter receiving temozolomide, the subset of APNG negative tumors was reported to 
have a better prognosis. Peroxiredoxin 1 (PRDX1) is another interesting candidate, especially in the group of 
anaplastic astrocytomas. The PRDX1 promoter was found to be frequently hypermethylated in oligodendroglial 
tumors and secondary glioblastomas carrying a deletion of 1p/19q, leading to epigenetic down-regulation of 
PRDX1 expression 19. In this study, silencing of PRDX1 in Hs683 glioma cells sensitized these cells both to 
temozolomide and radiotherapy in vitro. 
The objective of our present study was to determine the prevalence and impact of recently defined biomarkers 
which are associated with survival, but were established in younger patients, in an elderly collective. We 
hypothesized that these biomarkers might help to explain the heterogeneity in survival seen in the NOA-08 
population. However, as our study revealed that they are virtually absent in elderly patients, we assume that 
relevant molecular differences exist between malignant glioma of different age groups, which warrant further 
studies. 
6 
 
 
MATERIALS AND METHODS 
Patients and DNA 
This study comprised 126 patients of the NOA-08 collective, nine with anaplastic astrocytomas (7.1%) and 117 
with glioblastomas (92.9%). All patients were 65 years or older 11. 
DNA from fresh-frozen paraffin-embedded (FFPE) tissue was extracted using the Invisorb Genomic DNA Kit II 
(Stratec Molecular, Berlin, Germany). Before DNA extraction, specimens were histopathologically reviewed and 
tumor content > 80% was confirmed. 
To complement our subset with a series of tumors from younger glioblastoma patients, we received bisulfite-
converted DNA of ten glioblastoma patients (mean age 45 years) from the Department of Neuropathology, 
University of Heidelberg (W.M.). 
 
IDH1 and H3F3A mutation status 
Patients were screened for IDH1 and H3F3A mutations by direct sequencing of PCR products or 
immunohistochemistry. For sequencing analysis, the following primers were used: 
IDH1: 5’-CGGTCTTCAGAGAAGCCATT-3' (for.), 5’-GCAAAATCACATTATTGCCAAC-3' (rev.) 
H3F3A: 5’-CATGGCTCGTACAAAGCAGA-3’ (for.), 5’-CAAGAGAGACTTTGTCCCATTTTT-3’ (rev.) 
Sequencing was performed by GATC Biotech, Konstanz, Germany. Immunohistochemistry detecting the 
IDH1R132H mutation was performed with mouse monoclonal antibody H09 (Dianova, Hamburg, Germany) on 
an automated immunostainer (BenchMark, Ventana Medical Systems, Tuscon, AZ, USA). 
 
G-CIMP status 
Methylation-specific PCRs (MSP) for 8 genes were performed as previously described 15. A sample was 
considered G-CIMP positive when either DOCK5 was hypo- and 5 of the remaining 7 genes were 
hypermethylated or (in case of a hypermethylation of DOCK5) 6 out of the other 7 genes were hypermethylated. 
Supplementary Table 1 lists the primers used for MSP analysis. 
 
Quantitative high resolution DNA methylation analysis 
APNG and PRDX1 promoter methylation was screened using the MassARRAY technique (Sequenom, San 
Diego, CA, USA). This technology relies on detection of mass shifts, which are introduced through sequence 
changes following bisulfite treatment 20. In short, 500 ng genomic DNA was bisulfite-converted using the Epitect 
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Bisulfite Kit (Qiagen, Hilden, Germany). For PCR amplification, HotStarTaq (Qiagen, Hilden, Germany) and 
the primers listed in Supplementary Table 2 were used. 
Next, DNA methylation analysis was performed on a Sequenom mass spectrometer and the results were 
analyzed by the Epityper software (Version 1.05, Sequenom, San Diego, CA, USA). 
 
Illumina 450k methylation array 
For genome-wide assessment of DNA methylation we used the HumanMethylation450 BeadChip (Illumina, San 
Diego, CA, USA). Methylation analysis of glioblastoma samples (n=22) was performed at the in-house 
Genomics and Proteomics Core Facility (German Cancer Research Center, Heidelberg, Germany). Methylation 
data of additional adult glioblastoma samples (n=74) were obtained from the database of The Cancer Genome 
Atlas (TCGA, http://cancergenome.nih.gov) at June 15 2012. 
 
TCGA collective 
To assess the influence of age on survival in IDH wild-type patients, methylation (Illumina 
HumanMethylation27 BeadChip, n=294 samples and Illumina HumanMethylation450 BeadChip, n=126 
samples) and clinical data were obtained from the database of The Cancer Genome Atlas (TCGA, 
http://cancergenome.nih.gov) at Jan 15 2013. 
Unsupervised hierarchical clustering of methylation data was performed as described previously 15,17. Briefly, 
probes (i) targeting the X and Y chromosomes, (ii) containing a single nucleotide polymorphism within 5 base 
pairs of and including the CpG site and (iii) not mapping uniquely to the human reference genome (hg19), 
allowing for one mismatch, were removed. The 1500 (Illumina HumanMethylation27 BeadChip) and 8000 
(Illumina HumanMethylation450 BeadChip) most variable (by SD) probes were kept and unsupervised 
hierarchical clustering was performed for each platform . 
A logistic regression model to estimate the probability of MGMT methylation from Illumina HumanMethylation 
BeadChip data was used as described by Bady et al 21: From the normalized methylated (m) and unmethylated 
(u) signal intensities, the M-value was calculated: M-value = log2(max(yi,methyl,0)+/ (max(yi,unmethyl, 0)+) 22. 
The probability of MGMT methylation was calculated as logit(y) = 4.3215 + 0.5271 * M-value(cg12434587) + 
0.9265 * M-value(cg12981137). A probability cut-off at 0.358 was used. 
 
 
Statistics 
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MassARRAY CpG units were evaluated separately as well as averaged per amplicon. Association of quantitative 
MassARRAY measurements with overall survival (OS) and event-free survival (EFS) was assessed with 
univariate Cox PH regression models. Predictive factors were assessed with a factor vs. treatment interaction 
term. Proportional hazards assumption was tested for violation according to Grambsch and Therneau 23. Risk 
groups were determined based on optimal cut-point analysis using the maximally selected log-rank statistic 
approach 24,25, which corrects for type I error inflation due to multiple testing. Survival of risk groups was 
estimated with the method of Kaplan and Meier. Wilcoxon rank-sum test was employed to compare median 
Karnofsky performance score between old and young subgroups of the TCGA data, Fisher’s exact test was used 
to analyze the relationship between age (dichotomised as < 65 and ≥ 65 years) and MGMT methylation, extent of 
surgery and treatment, respectively. Univariable p values were adjusted for multiple testing using Benjamini-
Hochberg correction in order to control the false discovery rate 26. All tests were two-sided. P values below 0.05 
were considered statistically significant. Analyses were carried out using software R Version 2.14 27. 
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RESULTS 
Study population 
In total, 126 patients of the NOA-08 trial (termed NOA-08 biomarker cohort) were analyzed. Table 1 lists the 
patient characteristics of this study collective and the NOA-08 collective. Patients with a resection rather than a 
biopsy are overrepresented in this cohort due to the requirement of a sufficient amount of tissue. MGMT 
promoter methylation status was similar between both groups. Median EFS times were comparable between our 
study population (4.4 months, 95% CI 3.7-5.4 months) and the entire NOA-08 collective (4.1 months, 95% CI 
3.7-4.5 months), while median overall survival was higher (11.2 [95% CI 9.5-13.6] vs. 8.9 [95% CI 8.0-9.9] 
months). Long-term OS data are demonstrating a group of patients with a considerably longer than average 
survival mainly in the temozolomide arm (Figure 1a). As expected from the increased median OS, these patients 
are overrepresented in our cohort due to enrichment of patients having undergone resection instead of biopsy. 
Supplementary Table 3 lists the EFS and OS data for all 126 patients included in this study. 
In the NOA-08 trial, histology (anaplastic astrocytoma vs. glioblastoma) did not significantly influence event-
free or overall survival 11. This is recapitulated in the present biomarker cohort, where histology has no influence 
on event-free or overall survival. Kaplan-Meier plots are depicted in Supplementary Figure 1. 
Importantly, the predictive value of MGMT promoter methylation for response to temozolomide is recapitulated 
in this NOA-08 biomarker cohort (interaction p=0.03 (OS) and <0.001 (EFS)). In a Cox regression model, 
MGMT promoter hypermethylation significantly prolonged EFS and OS in patients treated with temozolomide (p 
< 0.0001 and p=0.0014, respectively), while in the radiotherapy group, the influence of MGMT promoter 
methylation on survival was not significant (p=0.34 for EFS and p=0.14 for OS) (Figure 1b,c). 
  
IDH1 mutation, G-CIMP status and H3F3A mutations 
In this study cohort, three patients carried an IDH1 mutation in their tumor tissue as determined by sequencing. 
Of these, two patients had glioblastomas (out of 117 glioblastoma patients) and one had an anaplastic 
astrocytoma (out of 9 patients). The two glioblastoma patients had an overall survival of 582 and 924 days, 
respectively. This is above the median OS (272 (231-315 days) in the NOA-08 group, whereas the patient with 
an anaplastic astrocytoma had shorter than median survival (patient 37, OS 196 days). Notably, MGMT promoter 
analysis revealed hypermethylation in all 3 patients. On the other hand, only patient 110 received temozolomide 
as first-line treatment (Table 2).  
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To expand the sample size, we performed IDH1 immunohistochemistry on another 50 patients from the NOA-08 
trial of whom only unstained paraffin-embedded slides, but no tumor DNA for further analysis, were available. 
In this group, no IDH1(R132H) mutant tumor was detected. In summary, the low frequency of IDH1 mutations 
precludes a predictive role of this marker in elderly patients with glioblastoma, although individual patients may 
have a better course than the average. 
In line with earlier reports demonstrating a strong correlation between IDH1 mutations and G-CIMP, the eight-
gene MSP panel revealed that these three IDH1 mutant patients were also G-CIMP positive. In the remaining 
IDH1 wildtype group of 123 samples, 4 samples could not be analyzed due to insufficient DNA left for bisulfite 
conversion and the other 119 were G-CIMP negative. 
To screen our biomarker cohort for the recently described H3F3A K27M and G34R/V mutations, we amplified 
and sequenced a 170 bp fragment spanning the two mutation sites of the H3F3A gene in all 103 patients for 
which enough suitable DNA was left. We detected neither K27M nor G34R/V mutations in our cohort. 
 
APNG and PRDX1 methylation 
CpG methylation was assessed by MassARRAY technology. In total, 99 (APNG) and 73 (PRDX1) tumors of the 
126 sample cohort were analyzed. Methylation levels across the 20 examined CpGs (measured as 13 distinct 
CpG units) in the promoter / intron 1 of the APNG locus were low apart from a few exceptions (median 6%, 
interquartile range 5-9%). The heatmap of APNG methylation is depicted in Figure 2a. Mean quantitative CpG 
methylation levels of APNG were not associated with EFS (p=0.54) or OS (p=0.61). Similarly, discrimination 
between APNG methylated and APNG nonmethylated patients at a cut-off value of 10% (EFS, p=0.71) and 3% 
(OS, p=0.42), respectively, which optimally separated the curves, did not yield a significant risk stratification, 
independent of treatment. When analyzing the predictive effect of APNG methylation in patients with a 
nonmethylated MGMT promoter who were treated with temozolomide, the low methylation levels precluded 
identification of a biologically meaningful cutpoint (7.2% for OS and 8.5% for EFS, respectively). 
Since APNG has been proposed as a biomarker predictive for the benefit from temozolomide with average 
methylation levels varying between 30-40% (APNG expressers) and 70-80% (APNG non-expressers) 18, we next 
aimed at investigating reasons for that discrepancy to our findings. To exclude APNG as a biomarker relevant 
only for younger patients, we also did MassARRAY analyses on 10 patients with an average age of 45 years. 
This analysis yielded the same homogenously low methylation level as in the NOA-08 biomarker cohort (data 
not shown). In addition, Illumina 450k methylation arrays were performed for 22 patients from the NOA-08 
biomarker collective. Further, samples from the TCGA project, which were analyzed on the same Illumina 450k 
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platform (n=74, mean age 61 years, range 23 – 85 years), have been included. Two probes (cg05397937 and 
cg15768556) surveyed in total 3 CpGs, which are also included in both our MassARRAY amplicon and bisulfite 
sequencing performed by Agnihotri and colleagues (see Figure 2c). Consistent with the MassARRAY findings 
homogenously low levels of methylation are demonstrated across all 96 samples (< 0.2, see Figure 2d,e). Even 
though 5 TCGA samples clustered into the G-CIMP group 15, they did not show increased levels of APNG 
methylation compared to non-G-CIMP samples. Of note, comparing MassARRAY data and 450k data for the 
NOA-08 patients of whom both datasets were available showed a good agreement between both methods. 
Promoter methylation analysis of PRDX1 revealed moderately low methylation with most samples exhibiting a 
mean methylation between 10 and 20% across the 6 CpGs (measured as 5 distinct CpG units) examined (Figure 
2b). Only 8 out of 73 samples had a mean methylation > 30%. PRDX1 methylation did not show an association 
with EFS or OS, neither in the whole study population nor by treatment. 
 
Age-related survival differences 
Given the paucity of positive prognostic factors in older glioblastoma patients, we sought to determine whether 
the relative absence of these known factors alone might explain the survival differences seen between different 
age groups using the TCGA data set. We determined G-CIMP (as a surrogate marker for IDH mutation) and 
MGMT promoter methylation status from Illumina HumanMethylation BeadChip data as previously 
described15,17,21 and complemented these molecular data with clinical information from the TCGA database. In 
total, 170 patients had a complete clinical and molecular dataset. In this cohort, we detected 18 patients with a 
hypermethylator phenotype (10.5%), of which only 2 were older than 65 years. G-CIMP status was associated 
with a significantly prolonged survival (median overall survival 22.7 [95% CI 8.4-not reached] vs. 15.9 [95% CI 
14.1-17.6] months, logrank p=0.0085, Supplementary Figure 2a). MGMT promoter hypermethylation as 
predicted through a logistic regression model occurred in 70 cases (41%) and was associated with improved 
median overall survival in patients who initially received a combined radio-chemotherapy (19.7 [95% CI 15.7-
23.9] vs. 14.5 [95% CI 12.2-16.6] months, logrank p=0.0288, Supplementary Figure 2b). For further analysis, 
we excluded G-CIMP positive patients. Table 3 summarizes the baseline characteristics of both groups (G-
CIMP negative patients < 65 and ≥ 65 years of age). Notably, the two groups showed no significant differences 
with regards to relevant prognostic or predictive parameters, albeit there was a trend towards a higher Karnofsky 
performance score in the younger cohort. Despite the balance between the groups, older patients had a 
significantly shorter overall survival (12.5 [95% CI 7.6-14.4] vs. 17.6 [95% CI 15.7-20.3] months, logrank 
p=0.0007, Figure 3a). To account for a potential confounding effect of the Karnofsky performance score, we 
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performed a multivariate Cox regression analysis including age (as a dichotomous variable < 65 vs. ≥ 65 years of 
age) and Karnofsky performance score (as a categorical covariate). Conforming the above result, this analysis 
yielded a hazard ratio of 2.25 (95% CI 1.46-3.47, p < 0.001) for patients ≥ 65 years of age adjusted for 
Karnofsky performance score. 
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DISCUSSION 
Elderly patients will soon account for more than half of all glioblastoma patients in the Western countries 2. 
Despite this development, elderly patients are still underrepresented in clinical trials, leaving the standard care 
for this population currently ill-defined 3. There is increasing evidence to suggest fundamental molecular 
differences between malignant gliomas of different age groups. In 2004, Batchelor et al. demonstrated age-
dependent effects of the prognostic impact of key genomic alterations (TP53 mutation, CDK2NA/p16 deletion 
and loss of chromosome 1p) in glioblastoma 28. Recently, analysis of common genomic aberrations in 
glioblastoma (TP53 mutation, EGFR amplification, EGFR vIII mutant, PTEN deletion and IDH1 mutation) have 
revealed distinctive differences in the distribution of these aberrations in young adults (19 – 40 years of age) and 
patients older than 40 years 29. In the pediatric population, somatic mutations in the H3.3-ATRX-DAXX 
chromatin remodeling pathway have been discovered in 44% of glioblastomas 16. Tumors carrying a mutation in 
this pathway were associated with a distinct gene expression profile. It has recently been shown that tumors with 
H3.3 mutations have indeed a distinct methylation, gene expression, mutation and copy number variation profile 
and possibly cell of origin 17. Molecular analysis of glioblastomas across the age continuum showed that H3.3 
mutations (K27M and G34R/V) predominantly occurred in children and young adults and IDH mutations in 
young adults, while older patients mostly were classified into the remaining three subtypes (mesenchymal 
subtype, RTK 1 “PDGFRA” and RTK 2 “classic”). In agreement with this, IDH mutations are very rare in 
patients with malignant gliomas above the age of 60 14. The lack of IDH mutations in these tumors might 
partially contribute to the worse prognosis of elderly patients with malignant gliomas, even though the analysis 
of the TCGA collective suggests that also other factors play a role in these age-related survival differences. 
Along this line, we found only 3 IDH1 mutated patients in our cohort of 126 patients, and no H3F3A mutations. 
In agreement with the recently discovered causative role of IDH mutations in epigenetic remodeling resulting in 
a G-CIMP phenotype, our 3 IDH1 mutated samples proved G-CIMP positive as well 30,31. With IDH1 mutations 
accounting for more than 90% of IDH mutations in glioma13, the causality between IDH mutation and the G-
CIMP phenotype and the lack of a G-CIMP positive tumor in the remaining 119 IDH1 wildtype samples, we 
decided against testing for IDH2 mutations. Importantly, while the two glioblastoma patients carrying an IDH1 
mutation and G-CIMP had an overall survival above average (see Table 2), 15 IDH wildtype / G-CIMP negative 
patients in this study population had a comparable or even longer overall survival than patient 110, who is IDH 
mutated / G-CIMP positive. Of these 15 patients one patient displayed a longer overall survival than the IDH 
mutated / G-CIMP positive patient 125 (see Supplementary Table 3). 
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The rationale for the further selection the biomarkers investigated in this study was to explain the survival 
heterogeneity seen in the NOA-08 trial population, where a group of patients had a considerably longer survival 
than average11. MGMT promoter methylation alone is not sufficient to account for this. In glioblastoma, key 
chromosomal, genetic and epigenetic aberrations have been defined, including EGFR amplification, TP53 
mutation, CDK4 amplification, CDKN2A homozygous deletion or IDH mutations 12,32. However, with the 
notable exception of IDH mutations 13, these molecular aberrations have no significant effect on survival 33. With 
regard to the aim of our study, we therefore limited the selection of biomarkers to prognostically relevant 
markers.   
A recent report demonstrated a role for the DNA repair enzyme APNG in conferring resistance to temozolomide 
in glioblastoma 18. Patients without hypermethylation of the MGMT promoter were subgrouped into APNG 
expressers and non-expressers (assessed by immunohistochemistry), where tumors that expressed APNG had a 
worse prognosis when treated with a temozolomide-containing regimen. To investigate the role of promoter 
methylation in regulation of APNG expression, these authors performed bisulfite sequencing of an 
approximately 200 bp fragment located in the promoter / intron 1 region of APNG. Comparing APNG expressers 
and non-expressers, differences in mean methylation levels across the investigated fragment (37 ± 5% for 
expressers and 77 ± 6% for non-expressers) were found. In vitro treatment of human glioblastoma cell lines with 
the demethylating agent 5-azacytidine resulted in up-regulation of APNG mRNA levels. This led the authors to 
propose that APNG expression is regulated through promoter hypermethylation. As the NOA-08 study and the 
present biomarker cohort clearly demonstrate the predictive effect of MGMT promoter hypermethylation 
described earlier 34, we sought to determine if APNG methylation also has the predictive value as proposed 
before. In contrast to Agnihotri and colleagues, we performed MassARRAY analysis of the same fragment, a 
well established technique for quantitative assessment of methylation 20. Surprisingly, we only detected <20% 
levels of APNG promoter methylation across all samples and CpG units (Figure 2) and did not observe the 
separation of patients into two groups. Since methylation is known to be at least partially age-dependent 35, we 
expanded our MassARRAY analysis to include ten younger glioblastoma patients (mean age 45 years) and 
obtained similar results. Our findings were confirmed through a technically and (partly) biologically independent 
analysis of Illumina 450k methylation arrays of 22 NOA-08 samples and 74 TCGA samples. The low 
methylation of APNG is no age-specific effect, as evidenced by the TCGA samples, which include patients aged 
between 23 and 85 years (mean age 61 years) and showed homogenously low methylation levels across all 
samples. Furthermore, the methylation-specific predictive effect of MGMT promoter methylation is highly 
significant in both our subset and the whole NOA-08 cohort. A possible explanation for the conflicting results 
15 
 
regarding APNG methylation may lie in the use of the non-quantitative bisulfite sequencing, which requires 
clonal amplification prior to sequencing, thus introducing an additional step for potential bias. Our APNG 
amplicon was marginally larger than that examined by Agnihotri et al. (233 bp vs. 193 bp), yet addressed exactly 
the same CpGs (Figure 2c). We carefully re-inspected our amplicon sequence with respect to possible SNPs in 
primer sequences and GC-content, being 41% after bisulfite treatment in case all CpGs would be methylated, 
and found no obvious hint for any PCR bias in our setting. Further studies will be required to assess the role of 
epigenetic regulation in APNG expression. 
Analysis of PRDX1 promoter methylation, a novel marker for sensitivity towards temozolomide or radiotherapy, 
yielded no significant effect on survival. This is in line with the original report on PRDX methylation, which 
suggested that hypermethylation mostly occurs in oligodendroglial tumors and secondary glioblastomas 19.  
Although the biomarker cohort analyzed in the present study was representative for the NOA-08 study 
population (Table 1), subgroup analyzes have well-known limitations. Further some DNA samples extracted 
from FFPE tissue proved to be too fragmented to allow for PCR amplification of the desired MassARRAY 
amplicons (each > 200 bp), explaining the discrepancy in analyzed samples between G-CIMP MSP (n=126, with 
average amplicon size of 100 bp) and MassARRAY (n=99 and 73 samples for APNG and PRDX1, respectively). 
To assess the influence of age on survival, we analyzed survival in a large cohort from the TCGA, which was 
well matched for all relevant prognostic factors. However, the median survival times of the TCGA collective are 
subject to a selection bias, e.g. due to the tissue requirements for molecular analysis (exemplified by a 90% 
resection rate, Table 3 versus 60% in NOA-08 11) and thus cannot be externally compared, e.g. to the NOA-08 
survival times. Nonetheless, in the intragroup comparison, patients aged ≥ 65 years still had significantly shorter 
overall survival times than their younger counterparts. 
In summary, favorable prognostic biomarkers such as IDH or H3F3A mutation, G-CIMP or PRDX1 methylation 
are virtually absent in malignant astrocytic tumors of the elderly which may partially account for the worsened 
prognosis of these patients. However, even in G-CIMP negative (and hence IDH wild-type) tumors, which are 
matched for known prognostic factors, older patients have a significantly shorter overall survival. On the other 
hand, several long-term surviving patients in our cohort exist which lack the aforementioned molecular markers 
and sometimes even MGMT promoter hypermethylation. These two observations strongly hint at the existence of 
so-far unknown prognostic factors in these patients. Further studies are necessary to broaden our insight into the 
molecular aberrations in elderly patients in order to step-wise replace chronological age as the most important 
negative prognostic marker and potentially therapy-decisive variable in malignant astrocytomas with defined and 
hopefully actionable molecular mechanisms. 
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FIGURE CAPTIONS 
Figure 1. Survival by MGMT promoter methylation status and treatment. (A) Unlimited Kaplan-Meier plots for 
OS of the radiotherapy (RT) and temozlomide (TMZ) group, respectively. (B-C) The Kaplan-Meier plots depict 
the relationship between MGMT promoter methylation and treatment for EFS (B) and OS (C). 
 
Figure 2. Analysis of APNG and PRDX1 methylation. (A-B) Heatmaps of APNG (A) and PRDX1 (B) promoter 
methylation. Each column represents a sample, each row a CpG unit. Methylation values are ranging from 0 
(totally unmetylated) to 1 (fully methylated) and are color-coded, the legend is shown left of the heatmaps. (C) 
Representation of the spatial relationship between the assessed CpGs of APNG. (D-E) Display of average 
methylation levels (beta values) for the TCGA (D) and NOA-08 (E) samples. 
 
Figure 3. Survival by age in the TCGA collective. (A) Overall survival of G-CIMP negative patients, stratified 
by age (< 65 vs. ≥ 65 years of age).
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RT, Radiotherapy; TMZ; Temozolomide 
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Supplementary Figure 1. Survival by histology. (A-B) Kaplan-Meier plots for event-free (A) and overall 
survival (B) grouped by histology (anaplastic astrocytoma vs. glioblastoma). 
 
Supplementary Figure 2. Survival in the TCGA collective by molecular markers. (A) Kaplan-Meier plot for 
overall survival, stratified by G-CIMP Status. (B) Overall survival depicted in patients who received 
radiotherapy plus temozolomide as first-line treatment, stratified by MGMT promoter methylation status. 
  
Supplementary Table 1: List of primers used for detecting the G-CIMP status 
Name Sequence 
M1-ANKRD43-for CGGTGTTGGGTTTTTTGTAGGAGTACGGC 
M1-ANKRD43-rev TCGCCGACATCGAACAACGA 
U1-ANKRD43-for TGGTGTTGGGTTTTTTGTAGGAGTATGGT 
U1-ANKRD43-rev TCACCAACATCAAACAACAA 
M1-DOCK5-for CGGTTCGCGGAGTTTAGC 
M1-DOCK5-rev AACTACTACAACTCCTCGAACTCCG 
U1-DOCK5-for TGGTTTGTGGAGTTTAGT 
U1-DOCK5-rev AACTACTACAACTCCTCAAACTCCA 
M1-HFE-for TTTTTGATGTTTTTGTAGATCGCG 
M1-HFE-rev CGCGCCCCTAATTCGC 
U1-HFE-for TTTTTGATGTTTTTGTAGATTGTG 
U1-HFE-rev CACACCCCTAATTCAC 
M1-LGALS3-for GCGGAGTTTCGTGGGTTTCG 
M1-LGALS3-rev AATAACCAAACTACGACTCGTCACC 
U1-LGALS3-for GTGGAGTTTTGTGGGTTTTG 
U1-LGALS3-rev AATAACCAAACTACAACTCATCACC 
M1-MAL-for GTTCGGTGTAGGATTTTAGCGTC 
M1-MAL-rev ATCTACAATAAAAAATAAAACCGACCG 
U1-MAL-for GTTTGGTGTAGGATTTTAGTGTT 
U1-MAL-rev ATCTACAATAAAAAATAAAACCAACCA 
M1-RHOF-for GTTGCGGGTTTCGGGTAATGGATGTT 
M1-RHOF-rev ACCGCAACCGCCGTCGCCCACG 
U1-RHOF-for GTTGTGGGTTTTGGGTAATGGATGTT 
U1-RHOF-rev ACCACAACCACCATCACCCACA 
M1-FAS1-for AGGAACGTTTTGGGATAGGAA 
M1-FAS1-rev CAACTTAACCTACGCGCGAAT 
U1-FAS1-for AGGAATGTTTTGGGATAGGAA 
U1-FAS1-rev CAACTTAACCTACACACAAAT 
M1-FAS2-for GGGTAGGAGGTCGGTTTTCG 
M1-FAS2-rev TTCGTTACACAAATAAACATTCCTATCC 
U1-FAS2-for GGGTAGGAGGTTGGTTTTTG 
U1-FAS2-rev TTCATTACACAAATAAACATTCCTATCC 
 
 
Supplementary Table 2: MassARRAY primer for APNG and PRDX1 promoter methylation 
Name Sequence (5’-3’) 
APNG_for aggaagagagGGGTAGAGTTAGAGTATAGGTTAAGGG 
APNG_rev cagtaatacgactcactatagggagaaggctCTAATCTTTAACAACACCTAAATCCTCCTAAC 
PRDX1_for aggaagagagTGAAGGAAGTTATTTAAGTTATGAGGG 
PRDX1_rev cagtaatacgactcactatagggagaaggctAAACCAAAATTCTCTTTACTTCCAAA 
 Supplementary Table 3: Survival data for all 126 patients included in this study 
Patient ID EFS (days) OS (days) 
1 34 34 
2 48 48 
3 52 52 
4 60 60 
5 62 62 
6 63 63 
7 68 70 
8 47 84 
9 89 89 
10 89 89 
11 97 97 
12 84 98 
13 75 99 
14 95 102 
15 106 106 
16 110 110 
17 111 111 
18 114 114 
19 115 115 
20 112 127 
21 51 129 
22 129 129 
23 94 132 
24 137 137 
25 138 138 
26 143 143 
27 150 150 
28 154 154 
29 74 154 
30 42 161 
31 89 169 
32 107 169 
33 73 171 
34 186 186 
35 102 190 
36 35 192 
37 196 196 
38 208 208 
39 209 209 
40 71 210 
41 212 212 
42 75 214 
43 105 215 
44 90 227 
45 110 228 
46 99 234 
47 236 236 
48 78 240 
49 246 246 
50 79 247 
51 228 261 
52 264 264 
53 180 265 
54 222 269 
55 130 270 
56 122 282 
57 84 288 
58 99 289 
59 134 289 
60 292 292 
61 97 297 
62 223 299 
63 108 300 
64 193 311 
65 181 312 
66 163 313 
67 206 325 
68 194 334 
69 188 340 
70 112 347 
71 100 351 
72 165 357 
73 78 366 
74 83 388 
75 176 392 
76 97 402 
77 209 409 
78 309 410 
79 211 412 
80 123 414 
81 256 416 
82 419 419 
83 223 421 
84 169 422 
85 424 424 
86 103 428 
87 139 436 
88 154 449 
89 159 450 
90 286 450 
91 265 455 
92 119 458 
93 126 460 
94 99 466 
95 166 467 
96 103 468 
97 232 479 
98 488 488 
99 495 495 
100 296 505 
101 321 507 
102 517 517 
103 429 524 
104 90 541 
105 230 541 
106 105 551 
107 168 552 
108 202 568 
109 265 573 
110 582 582 
111 93 609 
112 103 624 
113 138 642 
114 134 657 
115 236 674 
116 619 688 
117 510 690 
118 490 692 
119 516 706 
120 98 754 
121 89 768 
122 151 784 
123 81 817 
124 556 841 
125 924 924 
126 390 961 
Bold patients are IDH mutated / G-CIMP positive 
TABLES 
Table 1: Comparison of patient characteristics of this study population and the NOA-08 collective 
 This study population (n=126) NOA-08 (n=373) 
Histology 
Anaplastic astrocytoma 
Glioblastoma 
Not confirmed 
 
9 (7%) 
117 (93%) 
0 
 
40 (11%) 
331 (89%) 
2 
Treatment 
Temozolomide 
Radiotherapy 
 
62 (49%) 
64 (51%) 
 
195 (52%) 
178 (48%) 
Resection 
Complete 
Partial 
Biopsy 
Missing 
 
44 (35%) 
52 (41%) 
30 (24%) 
0 
 
104 (28%) 
123 (33%) 
145 (39%) 
1 
MGMT promoter 
Methylated 
Unmethylated 
Missing / Inconclusive 
 
42 (35%) 
77 (65%) 
7 
 
73 (35%) 
136 (65%) 
164 
 
  
Table 2: IDH mutated / G-CIMP positive patients. Note that patients 37 and 110 died without previous 
progression, while patient 125 had no progression until end of follow-up.  
Patient ID Histology Treatment MGMT EFS (days) OS (days) 
37 AA RT M 196 196 
110 GB TMZ M 582 582 
125 GB RT M 924 924 
GB, glioblastoma; AA, anaplastic astrocytoma; TMZ, temozolomide; RT, radiotherapy; M, methylated 
  
Table 3: Baseline characteristics of the TCGA collective 
 Patients < 65 years of age 
(n = 110) 
Patients ≥ 65 years of age 
(n = 42) 
 
Mean age, years (range) 51,6 (23 – 64) 71,9 (65 – 83) p < 0.0001 
Median Karnofsky 
performance score (range) 
80 (40 – 100) 80 (40 – 100) p=0.0737 
Extent of operation 
Resection 
Biopsy 
 
97 (88%) 
13 (12%) 
 
37 (88%) 
5 (12%) 
p=1.0 
Initial treatment 
RT + TMZ 
RT alone 
 
91 (83%) 
19 (17%) 
 
32 (65%) 
10 (24%) 
p=0.364 
MGMT promoter 
Methylated 
Unmethylated 
 
39 (35%) 
71 (65%) 
 
16 (38%) 
26 (62%) 
p=0.851 
 
